相关实验视频
Updated: Jan 14, 2026

10:29
Generation of Human Chimeric Antigen Receptor Regulatory T Cells
Published on: January 3, 2025
2.3K
在体外研究通过Kinsenoside对CAR-T功能的可逆调节
Guangmei Li1,2, Delian Zhou1,2, Shangwu Ning3
1Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
Molecular biology reports
|October 21, 2025
概括
一种新型的天然化合物kinsenoside (KD) 作为一个功能开关,可以安全地控制化学抗原受体T细胞 (CAR-T) 疗法. 这一发现为平衡CAR-T疗效和管理毒性提供了一种新方法.
科学领域:
- 免疫治疗是一种免疫疗法.
- 细胞疗法细胞疗法
- 药理学 药理学是指药理学的学科.
背景情况:
- 化学抗原受体T细胞 (CAR-T) 疗法在治疗癌症方面表现有前途.
- 目前的局限性包括缺乏控制过度CAR-T细胞扩张和相关毒性的方法.
研究的目的:
- 确定一种能够安全且可逆调节CAR-T细胞功能的天然化合物.
- 为了研究kinsenoside (KD) 作为CAR-T细胞活动的潜在调节者.
主要方法:
- 通过网络药理学结合虚拟查与体外实验验证.
- 被治疗的人类和CAR-T细胞KD,随后是药物戒断.
- 运用流动细胞计测功能测试 (增殖,细胞循环,细胞毒性) 和转录组分析来探索机制.
主要成果:
- 凯迪抑制了CAR-T细胞增殖,细胞周期进展和细胞毒性,同时降低了IL-6分泌.
- 在CAR-T细胞中,KD诱导了Th17细胞命运,通过Th17通路调节炎症,而不会改变CD4+/CD8+比率.
- 肯德基证明了良好的可逆性,可控性和低毒性.
结论:
- 基因化物作为CAR-T细胞的可控"功能开关"而起作用.
- 这为平衡CAR-T治疗疗效与毒性管理提供了一种新的策略.
- 突出了传统中医与现代细胞疗法的潜在整合.
相关概念视频
Receptor Downregulation in MVBs
2.8K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.8K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K

